pluristem therapeutics inc. (nasdaqcm: psti, tase: psti/pltr) is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3d) technology platform to develop cell therapies for conditions such as inflammation, ischemia, hematological disorders, or exposure to radiation. pluristem’s placental expanded (plx) cells are placenta-derived, mesenchymal-like adherent stromal cells that are designed to be administered to patients without the need for tissue or genetic matching. these cells release soluble biomolecules, such as cytokines, chemokines and growth factors, which act in a paracrine or endocrine manner to facilitate healing of damaged tissues by stimulating the body’s own regenerative mechanisms. the company’s proprietary, 3d expansion technology can be used to grow plx cells in mass quantities with batch-to-batch consistency at pluristem’s fda, ema and pmda-approved, state-of-the art manufacturing facility. pluristem’s first product candi
Company profile
Ticker
PLUR
Exchange
Website
CEO
Yaky Yanay
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AI SOFTWARE INC, PLURISTEM LIFE SYSTEMS INC, PLURISTEM THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Pluri Biotech Ltd. • Pluristem GmbH, incorporated • Plurinuva Ltd. ...
IRS number
980351734
PLUR stock data
Latest filings (excl ownership)
8-K
Other Events
17 Apr 24
8-K
Material Modifications to Rights of Security Holders
1 Apr 24
424B5
Prospectus supplement for primary offering
13 Feb 24
8-K
Entry into a Material Definitive Agreement
13 Feb 24
10-Q
2024 Q2
Quarterly report
12 Feb 24
8-K
Other Events
24 Jan 24
8-K
Other Events
8 Jan 24
10-Q
2024 Q1
Quarterly report
13 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Oct 23
EFFECT
Notice of effectiveness
22 Sep 23
Latest ownership filings
SC 13G/A
Shayna LP
13 Feb 24
SC 13G/A
Slager David Mark
1 Feb 24
4
Chen Franco-Yehuda
25 Jan 24
4
Zami Aberman
25 Jan 24
4
Pinhas Doron Birger
25 Jan 24
4
Maital Shemesh-Rasmussen
25 Jan 24
4
YAKY YANAY
25 Jan 24
4
Rami Avraham Levi
25 Jan 24
4
Lorne Kenneth Abony
25 Jan 24
SC 13G/A
Shayna LP
15 Sep 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.16 mm | 6.16 mm | 6.16 mm | 6.16 mm | 6.16 mm | 6.16 mm |
Cash burn (monthly) | 32.33 k | 322.67 k | 1.79 mm | 2.14 mm | 1.95 mm | 1.76 mm |
Cash used (since last report) | 215.11 k | 2.15 mm | 11.92 mm | 14.25 mm | 12.99 mm | 11.70 mm |
Cash remaining | 5.94 mm | 4.01 mm | -5.77 mm | -8.09 mm | -6.83 mm | -5.54 mm |
Runway (months of cash) | 183.8 | 12.4 | -3.2 | -3.8 | -3.5 | -3.2 |
Institutional ownership, Q2 2023
14.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 33 |
Opened positions | 3 |
Closed positions | 4 |
Increased positions | 6 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 412.39 mm |
Total shares | 6.07 mm |
Total puts | 0.00 |
Total calls | 31.40 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Shayna | 3.89 mm | $3.91 mm |
Slager David Mark | 1.55 mm | $0.00 |
Renaissance Technologies | 105.20 k | $84.00 k |
Bridgeway Capital Management | 102.60 k | $82.29 mm |
Meitav Dash Investments | 82.67 k | $66.30 mm |
Prime Capital Investment Advisors | 61.78 k | $49.55 mm |
Values First Advisors | 50.51 k | $40.51 mm |
Nia Impact Advisors | 38.29 k | $28.72 mm |
Jane Street | 37.01 k | $29.68 mm |
Zurcher Kantonalbank | 25.52 k | $20.47 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Jan 24 | Chen Franco-Yehuda | Common Stock | Grant | Acquire A | No | No | 0 | 355,000 | 0.00 | 472,716 |
23 Jan 24 | Zami Aberman | Common Stock | Grant | Acquire A | No | No | 0 | 44,100 | 0.00 | 1,536,073 |
23 Jan 24 | Pinhas Doron Birger | Common Stock | Grant | Acquire A | No | No | 0 | 39,900 | 0.00 | 59,900 |
23 Jan 24 | Maital Shemesh-Rasmussen | Common Stock | Grant | Acquire A | No | No | 0 | 38,150 | 0.00 | 58,150 |
23 Jan 24 | Yaky Yanay | Common Stock | Grant | Acquire A | No | No | 0 | 700,000 | 0.00 | 2,460,125 |
News
12 Health Care Stocks Moving In Monday's After-Market Session
8 Apr 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
8 Apr 24
Pluri Introduces Groundbreaking Immune Cell Expansion Technology, Secures New US Patent
8 Apr 24
Pluri Receives Patent Approval For 3D Bioreactor Technology In Plant Cell Cultivation
11 Mar 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
24 Jan 24
Press releases
Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
28 Mar 24
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
19 Mar 24
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
14 Mar 24
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
6 Mar 24
Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis
23 Jan 24